Cancer is a clonal disease, ie, all tumor cells within a malignant lesion trace their lineage
back to a precursor somatic cell that acquired oncogenic mutations during development and …

Lung cancer maintains a high morbidity and mortality rate globally despite significant
advancements in detection and therapy in the era of precision medicine. Excisional biopsy …

Purpose: In patients with> 1 non–small cell lung carcinoma (NSCLC), the distinction
between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) …

Background Diagnosing and treating patients with multiple primary lung cancers (MPLCs)
bring challenges to the clinic, and the preliminary evidence has revealed unsatisfying …

In recent decades, multiple primary lung cancer (MPLC) has been increasingly prevalent in
clinical practice. However, many details about MPLC have not been completely settled, such …

Introduction Genomic technologies present a promising mechanism of resolving the clinical
dilemma of distinguishing independent primary tumors from intrapulmonary metastases in …

Introduction With the advancements in early diagnosis, more and more patients with multiple
primary lung cancer (MPLC) have been identified. However, the progression of MPLC …

Resistance to epidermal growth factor receptor (EGFR) inhibitors, from the first-generation
erlotinib to the third generation osimertinib, is a clinical challenge in the treatment of patients …

With the widespread implementation of lung cancer screening, more and more patients are
being diagnosed with multiple primary lung cancers (MPLCs). In the era of precision …

High-throughput sequencing can be used to measure changes in tumor composition across
space and time. Specifically, comparisons of pre-and post-treatment samples can reveal the …